Sarah Farr
University of Toronto
16 Papers
79 Citations
Sarah Farr is an academic researcher from University of Toronto. The author has contributed to research in topics: Chylomicron & Postprandial. The author has an hindex of 11, co-authored 15 publications. Previous affiliations of Sarah Farr include SUNY Downstate Medical Center.
Chat about Author
Papers
GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance.
Jennifer Taher,Christopher Baker,Carmelle Cuizon,Hassan Masoudpour,Rianna Zhang,Sarah Farr,Mark Naples,Celine Bourdon,Zdenka Pausova,Khosrow Adeli +9 more
TL;DR: Exendin-4 prevents fructose-induced dyslipidemia and hepatic VLDL overproduction in insulin resistance through an indirect mechanism involving altered energy utilization, decreased hepatic lipid synthesis and also requires an intact parasympathetic signaling pathway.
86
Metabolic control via nutrient-sensing mechanisms: role of taste receptors and the gut-brain neuroendocrine axis
TL;DR: Gastrointestinal sensing mechanisms result in the transmission of neuronal signals to the brain through the release of gastrointestinal hormones that act on vagal and enteric afferents in order to modulate the physiological response to nutrients.
66
Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states.
TL;DR: Current evidence supporting a role for GLP-1 in preventing elevated intestinal chylomicron output and postprandial hypertriglyceridemia and investigating the current controversy over whether these effects could occur via direct receptor stimulation or alternative, indirect pathways is described.
52
Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states.
Sarah Farr,Khosrow Adeli +1 more
TL;DR: Evidence supporting a beneficial effect of incretin-based therapies on diabetic dyslipidemia through modulation of intestinal lipoprotein metabolism is summarized, as this offers a major new therapeutic approach to reduce cardiovascular risk in type 2 diabetic patients.
42
Intestinal scavenger receptor class B type I as a novel regulator of chylomicron production in healthy and diet-induced obese states.
Marsel Lino,Sarah Farr,Christopher A. Baker,Mark T Fuller,Bernardo L. Trigatti,Khosrow Adeli +5 more
TL;DR: It is concluded that intestinal SR-BI is a critical regulator of postprandial lipoprotein production, emphasizing its potential as a target for preventing diabetic dyslipidemia.
23